Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 13INDUSTRY 7UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1

Interventions

spartalizumab 2Rituximab 2tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegaspargase 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Oxaliplatin 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lenalidomide 1Idarubicin 1Gemcitabine 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × tislelizumab × Lymphoid × Clear all
NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

ChineseAMS

Phase 2 Unknown
54 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡